BridgeMD
New treatment option for Renal Cell Carcinoma (Kidney Cancer)
Official title Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
ClinicalTrials.gov ID: NCT07028125
What this study is testing
What is cabozantinib and nivolumab?
cabozantinib and nivolumab is an investigational medicine, given as an once-weekly infusion into a vein, being studied as a potential treatment for renal cell carcinoma (kidney cancer).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient older than 18 years
- Diagnosis of advanced/metastatic Renal Cell Carcinoma (RCC) with a clear-cell component
- No prior systemic treatment for RCC
- Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, in first line for advanced/metastatic...
- Female people of childbearing potential must not be pregnant at screening and during treatment by Cabozantinib and Nivolumab. Effective methods of...
You likely can't join if
- Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
- Current participation in another clinical study and/or in an investigational program with any intervention that could possibly interfere with the...
- Patient with history of allergy or hypersensitivity to components of the study drugs
- Patient with contraindication to the study drugs
- Pregnant or lactating woman
- Patient unable to use digital tools
See the full eligibility criteria
- Patient older than 18 years
- Diagnosis of advanced/metastatic Renal Cell Carcinoma (RCC) with a clear-cell component
- No prior systemic treatment for RCC
- Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, in first line for advanced/metastatic RCC, according to approved local labels
- Female people of childbearing potential must not be pregnant at screening and during treatment by Cabozantinib and Nivolumab. Effective methods of contraception must be used throughout the course of treatment and for at...
- Subject affiliated to an appropriate social security system
- Patient has signed informed consents obtained before any trial related activities and according to local guidelines
- Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
- Current participation in another clinical study and/or in an investigational program with any intervention that could possibly interfere with the treatment and impact this study
- Patient with history of allergy or hypersensitivity to components of the study drugs
- Patient with contraindication to the study drugs
- Pregnant or lactating woman
- Patient unable to use digital tools
- Patient deprived of liberty or placed under the authority of a tutor
- Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
The study team makes the final eligibility decision.
Where it's taking place
- Annecy, France
- Avignon, France
- Bayeux, France
- Boulogne-sur-Mer, France
- Caen, France
- Coudekerque-Branche, France
- Creil, France
- Dijon, France
- Lorient, France
- Lyon, France
- Montpellier, France
- Mulhouse, France
- Nice, France
- Poitiers, France
- Saint-Etienne, France
- Suresnes, France
- Tours, France
- Vannes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Annecy, France; Avignon, France; Bayeux, France; Boulogne-sur-Mer, France; Caen, France; Coudekerque-Branche, France and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.